Johnson & Johnson offered $8.9 billion to settle years-old lawsuits claiming that its talcum powder products caused cancer.
The New Jersey-based pharmaceutical giant described their proposal, which still needs a bankruptcy court’s approval, as an equitable and efficient resolution to all claims arising from cosmetic talc litigation.
If approved by the bankruptcy court and a majority of the claimants, the $8.9 billion deal would rank alongside those reached by cigarette corporations and opioid producers as one of the largest product liability settlements ever in the US
Thousands of claims have been filed against J&J because of talcum powder that may have contained traces of asbestos and was linked to ovarian cancer.
The company has never acknowledged wrongdoing, but as of May 2020, it no longer sells its talc-based baby powder in the US and Canada.
The $8.9 billion would be paid to the tens of thousands of claimants over 25 years through a J&J subsidiary, LTL Management LLC, which was set up to address the claims and has filed for bankruptcy protection.
A previous settlement involving LTL was rejected by an appellate court.


Japanese Yen Rebounds as Trump Flags Currency Weakness
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals
Dollar Holds Near Two-Month High as Yen Approaches 160
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
US Backs Musk in Fight Against EU’s €120 Million X Fine
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe
SpaceXAI to Double Nvidia Chips at Colossus 2 by Year-End
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
France Defends Netanyahu Airspace Clearance Despite ICC Warrant
US Judge Dismisses Imran Ahmed Deportation Lawsuit
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Asian Stocks Fall as Surging Bond Yields Rattle Markets 



